Cytokine gene expression in kidney allograft donor biopsies after cold ischemia and reperfusion using in situ RT-PCR

D Kaminska1, B Tyran, O Mazanowska

  • 1Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Poland. dorotakaminska@interia.pl

Insights

Cold ischemia and reperfusion in kidney transplants increase interleukin-6 (IL-6) mRNA expression in tubules, linked to longer cold ischemia times. Interferon-gamma (IFN-gamma) expression remained stable, suggesting early inflammation involves monocyte products.

Area of Science:

  • Transplantation immunology
  • Renal pathology
  • Molecular biology

Background:

  • Ischemia-reperfusion injury (IRI) is a critical factor impacting transplanted organ function.
  • Early inflammatory responses post-transplantation can significantly affect graft outcomes.
  • Understanding intragraft molecular changes is crucial for mitigating IRI.

Purpose of the Study:

  • To investigate changes in intragraft cytokine messenger RNA (mRNA) expression in kidneys following cold ischemia (CI) and reperfusion.
  • To specifically assess the expression of interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) mRNA in renal allografts.

Main Methods:

  • Analysis of renal needle core biopsies from eleven kidney transplant donors.
  • Assessment of IFN-gamma and IL-6 mRNA expression in tubular and glomerular compartments using in situ RT-PCR.
  • Evaluation of expression levels post-cold ischemia and after reperfusion.

Main Results:

  • A significant increase in IL-6 mRNA expression was observed in tubules post-reperfusion in most specimens.
  • IFN-gamma mRNA expression (tubular and glomerular) and glomerular IL-6 mRNA expression remained stable.
  • Higher mean CI times correlated with more intense IL-6 mRNA upregulation in tubules.

Conclusions:

  • Early inflammatory changes in renal allografts are primarily associated with monocyte/macrophage-derived products like IL-6.
  • The intensity of IL-6 expression in tubules is linked to the duration of cold ischemia.
  • Targeting early inflammatory mediators may be beneficial in reducing IRI severity.